skip to content
Dovepress - Open Access to Scientific and Medical Research
View our mobile site

8852

Evaluation of alcaftadine 0.25% ophthalmic solution in acute allergic conjunctivitis at 15 minutes and 16 hours after instillation versus placebo and olopatadine 0.1%

Original Research

(2522) Views  (648) Full article downloads

Authors: Jack V Greiner, Kimberly Edwards-Swanson, Avner Ingerman

Published Date January 2011 Volume 2011:5 Pages 87 - 93
DOI: http://dx.doi.org/10.2147/OPTH.S15379

Jack V Greiner1,2, Kimberly Edwards-Swanson3, Avner Ingerman4
1Schepens Eye Research Institute, Boston, MA; 2Department of Ophthalmology, Harvard Medical School, Boston, MA; 3Johnson & Johnson Consumer and Personal Products Worldwide, Skillman, NJ; 4Ora Inc, Andover, MA, USA

Purpose: To evaluate the effectiveness of alcaftadine 0.05%, 0.1%, and 0.25% ophthalmic solutions in treating the signs and symptoms of allergic conjunctivitis when compared with olopatadine hydrochloride 0.1% and placebo using the conjunctival allergen challenge (CAC) model.
Methods: One hundred and seventy subjects were randomized and 164 subjects completed all visits. CAC was performed to determine and confirm subjects’ eligibility at visits 1 and 2, respectively. The CAC was repeated at visit 3 (day 0 ± 3), 16 hours after study medication instillation, and at visit 4 (day 14 ± 3), 15 minutes after instillation. Ocular itching and conjunctival redness were evaluated after an allergen challenge, along with several secondary endpoints.
Results: Alcaftadine 0.25% and olopatadine 0.1% treatments exhibited significantly lower mean scores compared with placebo for ocular itching and conjunctival redness at visits 3 and 4. Most adverse events were self-limiting and mild in severity. No serious treatment-related adverse events occurred.
Conclusion: Treatment with alcaftadine 0.25% ophthalmic solution resulted in mean differences of >1 unit (ocular itching) and approximately >1 unit (conjunctival redness), which was significant (P < 0.001) compared with placebo treatment. All doses of alcaftadine were safe and well tolerated in the population studied.

Keywords: alcaftadine, allergic conjunctivitis, conjunctival allergen challenge




 

Other articles by Dr James McLaughlin



Readers of this article also read:

Evidence-based decision-making within the context of globalization: A “Why–What–How” for leaders and managers of health care organizations
Role of aliskiren in cardio-renal protection and use in hypertensives with multiple risk factors
Economic considerations in the treatment of invasive aspergillosis: a review of voriconazole pharmacoeconomic studies
Safety and efficacy of changing to the travoprost/timolol maleate fixed combination (DuoTrav) from prior mono- or adjunctive therapy
Comparison of effects of alcaftadine and olopatadine on conjunctival epithelium and eosinophil recruitment in a murine model of allergic conjunctivitis
Olmesartan/amlodipine: a review of its use in the management of hypertension
Clinical use of gatifloxacin ophthalmic solution for treatment of bacterial conjunctivitis
Evaluation of olopatadine 0.2% in the complete prevention of ocular itching in the conjunctival allergen challenge model
Erratum
Comparative efficacy of topical tetracaine solution versus lidocaine gel in cataract surgery